Search
  • Our Company
    • Overview
    • Leadership
    • Board of Directors
  • Programs
    • Pipeline
    • IBD
    • NASH
    • Publications
  • Investors
    • Overview
    • News Releases
    • Events & Presentations
    • Stock Information
    • Corporate Governance
      • Governance Documents
      • Committee Composition
    • Financials & Filings
      • Sec Filings
    • Investor Resources
      • Email Alerts
      • IR Contact
      • FAQs
  • News
  • Careers
  • Contact

There are more than 3 million people in the United States with IBD.

There are more than 3 million people in the United States with IBD.

Our Company

We are a clinical-stage biopharmaceutical company pioneering differentiated therapies for patients with GI and liver diseases.

Latest News
December 27, 2021

Metacrine Announces Resignation of Chief Medical Officer

November 11, 2021

Metacrine Reports Third-Quarter 2021 Results

Programs

Our most advanced program targets the farnesoid X receptor (FXR) which is central to modulating GI and liver diseases.

© 2022 Metacrine   |   3985 Sorrento Valley Blvd., Suite C, San Diego, CA 92121
  • Our Company
    ▼
    • Overview
    • Leadership
    • Board of Directors
  • Programs
    ▼
    • Pipeline
    • IBD
    • NASH
    • Publications
  • Investors
    ▼
    • Overview
    • News Releases
    • Events & Presentations
    • Stock Information
    • Corporate Governance
      ▼
      • Governance Documents
      • Committee Composition
    • Financials & Filings
      ▼
      • Sec Filings
    • Investor Resources
      ▼
      • Email Alerts
      • IR Contact
      • FAQs
  • News
  • Careers
  • Contact